Leslie E. Donato - 23 Feb 2026 Form 4 Insider Report for Keenova Therapeutics plc

Role
Director
Signature
/s/ Mark Tyndall, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
23 Feb 2026
Net transactions value
$0
Form type
4
Filing time
25 Feb 2026, 20:47:26 UTC
Previous filing
18 Aug 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Donato Leslie E Director 440 ROUTE 22 EAST, SUITE 302, BRIDGEWATER /s/ Mark Tyndall, Attorney-in-Fact 25 Feb 2026 0001784795

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction Restricted Stock Units Award $0 +3,984 +82% $0.000000 8,866 23 Feb 2026 Ordinary Shares 3,984 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Upon vesting, each restricted stock unit ("RSU") will be settled in ordinary shares of the Issuer at one share per RSU.
F2 Each RSU will fully vest on February 23, 2027.
F3 Reflects that the Reporting Person received 820 additional RSUs resulting from the adjustment of the RSUs held by the Reporting Person immediately prior to the separation of Par Health, Inc. ("Par Health") from the Issuer on November 10, 2025, pursuant to the terms of the Employee Matters Agreement by and between the Issuer and Par Health.

Remarks:

This Form 4 constitutes a notice to the Issuer for purposes of Part V of the Companies Act 2014.